New pre-clinical research showcases exciting discovery into the role of prebiotic ingredient, Bimuno GOS in reducing Branched Short Chain Fatty Acids (bSCFA)
Clasado Biosciences has in partnership with ProDigest (Belgium), highlighted a new published study that showcases exciting findings into the modulating role of its prebiotic ingredient, Bimuno GOS on Short Chain Fatty Acids (SCFA), branched Short Chain Fatty Acids (bSCFA), ammonium and pH.
The new study, ‘Galactooligosaccharide (GOS) Reduces Branched Short-Chain Fatty Acids, Ammonium, and pH in a Short-Term Colonic Fermentation Model’, demonstrates Bimuno GOS’ influence on reducing unfavourable metabolites; bSCFAs and ammonium, whilst also indicating an association of increasing health-positive metabolites; Short Chain Fatty Acid (SCFAs), including butyrate. This new research further strengthens the important role of prebiotics in supporting gastrointestinal and immune health.
The study also demonstrated a reduction of proteolytic fermentation, which further points towards the potential role of prebiotics in optimising the gut microbiome composition in the context of high-protein diets.
The pre-clinical discovery exercise, available to view on Open Access, was conducted as an international joint study between contract research organisation (CRO) ProDigest and Clasado. The results of the study further underpin the science behind Bimuno GOS, including increasing levels of bifidobacteria – the beneficial bacteria associated with positive health outcomes.
Around the globe, we are seeing growing consumer appetite for prebiotics, as the importance of gut health comes to the forefront
Dr Lucien Harthoorn, R&D Director at Clasado, explains the significance: “Gut health science advances at speed, and with each new published study we get a stronger glimpse of where the potential lies. This new publication is a prime example of why the prebiotics category is growing and further underpins the solid body of evidence behind Bimuno GOS.
“Among the findings, Bimuno GOS was found to reduce unfavourable metabolites including Branched Short Chain Fatty Acids and Ammonia, and increase favourable metabolites including acetate and butyrate, which are important SCFAs for the body. The result is a more advantageous gut environment for the host.
“The scientific principles that underpin our ingredient are already some of the strongest on the market and with each new study, we are seeing further evidence of Bimuno GOS’ effect on health outcomes. Matching up historic data with new findings gives the health and nutrition formulators added confidence in the documented effects of prebiotic functional ingredients.
The publication is the latest to support the exciting potential of Bimuno GOS in supporting human health. The galactooligosaccharide is the most studied of its kind on the market, supported by over 100 scientific publications, including more than 20 clinical trials.
Dr Harthoorn added: “Around the globe, we are seeing growing consumer appetite for prebiotics, as the importance of gut health comes to the forefront. Of course, as consumers look for products they can trust, the scientific backing of prebiotic ingredients comes under the microscope. This latest study further strengthens the advantages of Bimuno GOS, and marks it as an effective choice for nutritional formulations.”
